Achieve Life Sciences (ACHV) Director Waldman Reid Alexander Receives Awards

What Happened Waldman Reid Alexander, a director of Achieve Life Sciences, received equity awards on July 27, 2026 totaling 41,700 derivative securities: a grant of 25,000 options (derivative) and 16,700 restricted stock units (RSUs). Both awards were reported at an acquisition price of $0.00 (typical for compensatory grants) and do not reflect cash paid by the insider. These are awards/grants (not open-market purchases or sales) and are commonly part of board compensation.

Key Details

• Transaction date: July 27, 2026; Form 4 filed July 29, 2026 (timely).
• Grants: 25,000 derivative securities (options) and 16,700 RSUs, both shown at $0.00 acquisition price.
• Vesting: Options vest 100% on the earlier of July 27, 2027 or immediately prior to the issuer’s 2027 annual meeting, subject to continued service (Footnote F1). RSUs convert to one share apiece at settlement; they vest on the same schedule (Footnotes F2–F3).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication of a sale, tax withholding, 10b5-1 plan, or late filing in the provided information.

Context

• RSUs are a contingent right to receive common stock at settlement; they are not immediately tradable shares until vested and settled. The options/derivative grant similarly vests in full on the stated 2027 date, subject to continued service—this is a compensatory award rather than a market purchase or sale.
• Such grants are routine for directors as part of compensation and do not by themselves indicate the insider is buying or selling shares in anticipation of short-term stock moves.